Basal Cell Carcinoma (Basal Cell Epithelioma) - Pipeline Review, H2 2016

Published: Oct, 2016 | Pages: 112 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Basal Cell Carcinoma - Pipeline Review, H2 2016, provides an overview of the Basal Cell Carcinoma (Oncology) pipeline landscape.

Basal cell carcinoma is a type of skin cancer which begins in the basal cells. Symptoms include waxy bump, scaly, brown or flesh-colored patch and white, waxy scar. Predisposing factors include age, family history, and exposure to radiation and immunosuppressant medications. Treatment includes chemotherapy and surgery.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Basal Cell Carcinoma - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Basal Cell Carcinoma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Basal Cell Carcinoma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Basal Cell Carcinoma (Basal Cell Epithelioma) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I and Preclinical stages are 3, 5, 2 and 6 respectively for Basal Cell Carcinoma.

Basal Cell Carcinoma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Basal Cell Carcinoma (Oncology).
- The pipeline guide reviews pipeline therapeutics for Basal Cell Carcinoma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Basal Cell Carcinoma (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Basal Cell Carcinoma (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Basal Cell Carcinoma (Oncology)

Reasons To Buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Basal Cell Carcinoma (Oncology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Basal Cell Carcinoma (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

 Table of Contents

Table of Contents 2
List of Tables 4
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Basal Cell Carcinoma (Basal Cell Epithelioma) Overview 7
Therapeutics Development 8
Pipeline Products for Basal Cell Carcinoma (Basal Cell Epithelioma) - Overview 8
Basal Cell Carcinoma (Basal Cell Epithelioma) - Therapeutics under Development by Companies 9
Basal Cell Carcinoma (Basal Cell Epithelioma) - Pipeline Products Glance 10
Late Stage Products 10
Clinical Stage Products 11
Early Stage Products 12
Basal Cell Carcinoma (Basal Cell Epithelioma) - Products under Development by Companies 13
Basal Cell Carcinoma (Basal Cell Epithelioma) - Companies Involved in Therapeutics Development 14
Biofrontera AG 14
Biosceptre (Aust) Pty Ltd 15
Cannabis Science, Inc 16
Genextra S.p.a. 17
Ignyta, Inc. 18
Laboratories Ojer Pharma S.L. 19
MediGene AG 20
Merck & Co., Inc. 21
PellePharm, Inc. 22
Provectus Biopharmaceuticals, Inc. 23
Redx Pharma Plc 24
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. 25
Transgene SA 26
Basal Cell Carcinoma (Basal Cell Epithelioma) - Therapeutics Assessment 27
Assessment by Monotherapy Products 27
Assessment by Combination Products 28
Assessment by Target 29
Assessment by Mechanism of Action 31
Assessment by Route of Administration 33
Assessment by Molecule Type 35
Drug Profiles 37
aminolevulinic acid hydrochloride - Drug Profile 37
Product Description 37
Mechanism Of Action 37
R&D Progress 37
aminolevulinic acid hydrochloride - Drug Profile 41
Product Description 41
Mechanism Of Action 41
R&D Progress 41
BIL-010t - Drug Profile 42
Product Description 42
Mechanism Of Action 42
R&D Progress 42
BLR-300 - Drug Profile 43
Product Description 43
Mechanism Of Action 43
R&D Progress 43
CS-S/BCC-1 - Drug Profile 44
Product Description 44
Mechanism Of Action 44
R&D Progress 44
CSTATI-1 - Drug Profile 45
Product Description 45
Mechanism Of Action 45
R&D Progress 45
DAC-060 - Drug Profile 47
Product Description 47
Mechanism Of Action 47
R&D Progress 47
imiquimod SR - Drug Profile 48
Product Description 48
Mechanism Of Action 48
R&D Progress 48
Oshadi D + Oshadi R - Drug Profile 49
Product Description 49
Mechanism Of Action 49
R&D Progress 49
patidegib hydrochloride - Drug Profile 50
Product Description 50
Mechanism Of Action 50
R&D Progress 50
pembrolizumab - Drug Profile 51
Product Description 51
Mechanism Of Action 51
R&D Progress 51
PV-10 - Drug Profile 82
Product Description 82
Mechanism Of Action 82
R&D Progress 82
RDX-001 - Drug Profile 100
Product Description 100
Mechanism Of Action 100
R&D Progress 100
sinecatechins - Drug Profile 101
Product Description 101
Mechanism Of Action 101
R&D Progress 101
taladegib - Drug Profile 102
Product Description 102
Mechanism Of Action 102
R&D Progress 102
TG-1042 - Drug Profile 104
Product Description 104
Mechanism Of Action 104
R&D Progress 104
Basal Cell Carcinoma (Basal Cell Epithelioma) - Dormant Projects 106
Basal Cell Carcinoma (Basal Cell Epithelioma) - Discontinued Products 107
Basal Cell Carcinoma (Basal Cell Epithelioma) - Product Development Milestones 108
Featured News & Press Releases 108
Jul 28, 2016: Biofrontera Receives Favourable CHMP Assessment for Field-Directed Therapy and Files BCC Application 108
Jun 23, 2016: Biofrontera Progresses with Expansion of U.S. Subsidiary with Key Personnel Hires 108
Nov 19, 2015: Biofrontera reports final patient visit in phase III trial for basal cell carcinoma 109
Jul 22, 2014: Biosceptre Announces Positive Phase I Results for BIL-010t to Treat Basal Cell Carcinoma 109
Sep 24, 2012: Cannabis Science Initiates Preclinical Investigation Of CS-TATI-1 For European Studies For Squamous/Basal Cell Carcinomas And Kaposi's Sarcoma 110
Appendix 111
Methodology 111
Coverage 111
Secondary Research 111
Primary Research 111
Expert Panel Validation 111
Contact Us 111
Disclaimer 112

List of Tables

Number of Products under Development for Basal Cell Carcinoma (Basal Cell Epithelioma), H2 2016 8
Number of Products under Development by Companies, H2 2016 9
Comparative Analysis by Late Stage Development, H2 2016 10
Comparative Analysis by Clinical Stage Development, H2 2016 11
Comparative Analysis by Early Stage Development, H2 2016 12
Products under Development by Companies, H2 2016 13
Basal Cell Carcinoma (Basal Cell Epithelioma) - Pipeline by Biofrontera AG, H2 2016 14
Basal Cell Carcinoma (Basal Cell Epithelioma) - Pipeline by Biosceptre (Aust) Pty Ltd, H2 2016 15
Basal Cell Carcinoma (Basal Cell Epithelioma) - Pipeline by Cannabis Science, Inc, H2 2016 16
Basal Cell Carcinoma (Basal Cell Epithelioma) - Pipeline by Genextra S.p.a., H2 2016 17
Basal Cell Carcinoma (Basal Cell Epithelioma) - Pipeline by Ignyta, Inc., H2 2016 18
Basal Cell Carcinoma (Basal Cell Epithelioma) - Pipeline by Laboratories Ojer Pharma S.L., H2 2016 19
Basal Cell Carcinoma (Basal Cell Epithelioma) - Pipeline by MediGene AG, H2 2016 20
Basal Cell Carcinoma (Basal Cell Epithelioma) - Pipeline by Merck & Co., Inc., H2 2016 21
Basal Cell Carcinoma (Basal Cell Epithelioma) - Pipeline by PellePharm, Inc., H2 2016 22
Basal Cell Carcinoma (Basal Cell Epithelioma) - Pipeline by Provectus Biopharmaceuticals, Inc., H2 2016 23
Basal Cell Carcinoma (Basal Cell Epithelioma) - Pipeline by Redx Pharma Plc, H2 2016 24
Basal Cell Carcinoma (Basal Cell Epithelioma) - Pipeline by Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd., H2 2016 25
Basal Cell Carcinoma (Basal Cell Epithelioma) - Pipeline by Transgene SA, H2 2016 26
Assessment by Monotherapy Products, H2 2016 27
Assessment by Combination Products, H2 2016 28
Number of Products by Stage and Target, H2 2016 30
Number of Products by Stage and Mechanism of Action, H2 2016 32
Number of Products by Stage and Route of Administration, H2 2016 34
Number of Products by Stage and Molecule Type, H2 2016 36
Basal Cell Carcinoma (Basal Cell Epithelioma) - Dormant Projects, H2 2016 106
Basal Cell Carcinoma (Basal Cell Epithelioma) - Discontinued Products, H2 2016 107